News >

Lower-Dose Sorafenib Linked to Reduced Discontinuation Rate in HCC

Jason Harris
Published: Wednesday, Nov 15, 2017

Kim Reiss, MD

Kim Reiss, MD
Results from a retrospective, multi-institutional study showed that lowering the dose of sorafenib (Nexavar) for patients with hepatocellular carcinoma (HCC) reduced pill burden and treatment costs, while showing a trend toward improved treatment completion.

“After propensity score matching, [reduced-dose sorafenib] patients were less likely to discontinue sorafenib because of gastrointestinal toxicity, and there were trends toward a decreased risk of discontinuing the drug for any AE,” wrote Reiss et al. [Reduced-dose sorafenib] patients experienced decreased treatment cost and a trend toward a decreased incidence of discontinuing sorafenib because of AEs.”
Reiss KA, Yu S, Mamtani R, et al. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. J Clin Oncol. 2017;35(31):3575-3581. doi: 10.1200/JCO.2017.73.8245.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication